Addition of pembrolizumab to neoadjuvant chemotherapy (NACT) is a standard of care treatment in non-metastatic triple negative breast cancer (TNBC). Trials employing reduced doses of immune checkpoint inhibitors have yielded encouraging activity in several tumor types. Whether low-dose pembrolizumab enhances pathological complete response when added to NACT in triple-negative breast cancer remains uncertain.
A Phase II, Randomized, open-label study to evaluate low-dose Pembrolizumab plus Chemotherapy vs Chemotherapy as Neoadjuvant Therapy for localized Triple Negative Breast Cancer (TNBC). [PLANeT Trial – Pembrolizumab Low Dose in Addition to NACT in TNBC]
Annals of Oncology | | A. Arora, H. Bhaskarane, G. Tansir, S. Bakhshi, A. Gogia, A. Kumar, R. Jain, K. Kalra, D. Vishvam, S. Mathur, R. Rathore, S.A. Shamim, E. Dhamija, K. Rangarajan, P. Tanwar, C.P. Prasad, S. Kumar, I. Gupta, K. Mani, A.D. Upadhyay, M.K. Diwakar, P. Vasudeva, N. Verma, S. Agstam, V. Seenu, R. Prashad, V.K. Bansal, A. Dhar, A. Krishna, P. Ranjan, S. Suhani, O. Prakash, K. Kataria, B. Kumar, A. Mishra, J. Sharma, B. Bansal, J. Saikia, S. Bhasker, K.P. Haresh, S. Gupta, S.K. Saini, S. Mallick, A. Batra
Topics: breast-cancer, immunotherapy, chemotherapy, clinical-trials, research